1. Home
  2. ENTA vs ACV Comparison

ENTA vs ACV Comparison

Compare ENTA & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • ACV
  • Stock Information
  • Founded
  • ENTA 1995
  • ACV 2015
  • Country
  • ENTA United States
  • ACV United States
  • Employees
  • ENTA N/A
  • ACV N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • ACV Finance/Investors Services
  • Sector
  • ENTA Health Care
  • ACV Finance
  • Exchange
  • ENTA Nasdaq
  • ACV Nasdaq
  • Market Cap
  • ENTA 316.2M
  • ACV 253.6M
  • IPO Year
  • ENTA 2013
  • ACV N/A
  • Fundamental
  • Price
  • ENTA $12.65
  • ACV $24.52
  • Analyst Decision
  • ENTA Strong Buy
  • ACV
  • Analyst Count
  • ENTA 6
  • ACV 0
  • Target Price
  • ENTA $20.33
  • ACV N/A
  • AVG Volume (30 Days)
  • ENTA 387.8K
  • ACV 38.8K
  • Earning Date
  • ENTA 11-17-2025
  • ACV 01-01-0001
  • Dividend Yield
  • ENTA N/A
  • ACV 9.20%
  • EPS Growth
  • ENTA N/A
  • ACV N/A
  • EPS
  • ENTA N/A
  • ACV N/A
  • Revenue
  • ENTA $65,324,000.00
  • ACV N/A
  • Revenue This Year
  • ENTA $2.13
  • ACV N/A
  • Revenue Next Year
  • ENTA $2.74
  • ACV N/A
  • P/E Ratio
  • ENTA N/A
  • ACV N/A
  • Revenue Growth
  • ENTA N/A
  • ACV N/A
  • 52 Week Low
  • ENTA $4.09
  • ACV $16.82
  • 52 Week High
  • ENTA $15.34
  • ACV $23.74
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 66.08
  • ACV 43.10
  • Support Level
  • ENTA $11.89
  • ACV $24.40
  • Resistance Level
  • ENTA $13.00
  • ACV $25.19
  • Average True Range (ATR)
  • ENTA 0.83
  • ACV 0.39
  • MACD
  • ENTA 0.09
  • ACV -0.18
  • Stochastic Oscillator
  • ENTA 80.78
  • ACV 17.62

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest

Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.

Share on Social Networks: